key: cord-0863880-zfkw2fbo
authors: Clark, Sarah A.; Clark, Lars E.; Pan, Junhua; Coscia, Adrian; McKay, Lindsay G.A.; Shankar, Sundaresh; Johnson, Rebecca I.; Griffiths, Anthony; Abraham, Jonathan
title: Molecular basis for a germline-biased neutralizing antibody response to SARS-CoV-2
date: 2020-11-13
journal: bioRxiv
DOI: 10.1101/2020.11.13.381533
sha: d0a39af7e01fa4066fe0e36140a053a36fa34341
doc_id: 863880
cord_uid: zfkw2fbo

The SARS-CoV-2 viral spike (S) protein mediates attachment and entry into host cells and is a major target of vaccine and drug design. Potent SARS-CoV-2 neutralizing antibodies derived from closely related antibody heavy chain genes (IGHV3-53 or 3-66) have been isolated from multiple COVID-19 convalescent individuals. These usually contain minimal somatic mutations and bind the S receptor-binding domain (RBD) to interfere with attachment to the cellular receptor angiotensin-converting enzyme 2 (ACE2). We used antigen-specific single B cell sorting to isolate S-reactive monoclonal antibodies from the blood of a COVID-19 convalescent individual. The seven most potent neutralizing antibodies were somatic variants of the same IGHV3-53-derived antibody and bind the RBD with varying affinity. We report X-ray crystal structures of four Fab variants bound to the RBD and use the structures to explain the basis for changes in RBD affinity. We show that a germline revertant antibody binds tightly to the SARS-CoV-2 RBD and neutralizes virus, and that gains in affinity for the RBD do not necessarily correlate with increased neutralization potency, suggesting that somatic mutation is not required to exert robust antiviral effect. Our studies clarify the molecular basis for a heavily germline-biased human antibody response to SARS-CoV-2.

The SARS-CoV-2 pandemic has caused over 48 million infections with more than 1.2 74 million deaths worldwide. Vaccines and therapeutic agents are urgently needed, particularly as 75 certain parts of the world now face new waves of infections. The SARS-CoV-2 spike protein (S) 76 is a large and heavily glycosylated protein that forms trimers of heterodimers on the surface of 77 virions. Each S protomer has two functional subunits; S1, which contains a receptor-binding 78 domain (RBD) that binds to ACE2 1,2 , and S2, which mediates fusion of the viral and host cell 79 membranes during viral entry. 80

Epitopes for neutralizing antibodies on S include sites on the RBD and on the S1 N-81 terminal domain (NTD) 3-8 . IGHV3-53 or IGHV3-66 antibody genes are identical except for a single 82 amino acid mutation in an antibody framework region (FWR) 9 , and potent SARS-CoV-2 83 neutralizing antibodies derived from these two germline genes have been isolated from multiple 84 COVID-19 convalescent individuals 3,4,8,10-13 . The S RBDs can be in "down" or "up" 85 conformations 14, 15 , and ACE2 and IGHV3-53/3-66 neutralizing antibodies can only bind the RBD 86 when it is "up" 8, 16 . Although described IGHV3-53/3-66 neutralizing antibodies have short CDR H3 87 loops, some IGHV3-53 antibodies with longer CDR H3 loops can make contacts with neighboring 88

RBDs to close the trimer 17 . 89

Here, we used single B-cell sorting to isolate a panel of monoclonal antibodies that react 90 against the SARS-CoV-2 S protein from the memory B cells of a COVID-19 convalescent 91

individual. The most potent neutralizing antibodies were seven somatically related variants of a 92 single IGVH3-53-derived antibody that binds the RBD with varying affinity. We use X-ray crystal 93 structures of Fab/SARS-CoV-2 RBD complexes to explain the basis for gains or losses in RBD 94 affinity that occurred during antibody maturation. We show that a germline revertant of the 95 antibody binds tightly to the SARS-CoV-2 RBD and that gains affinity for the RBD are not 96 associated with higher neutralization potency. We propose that such a focused germline-biased 97 antibody to SARS-CoV-2 may be particularly vulnerable to antibody neutralization escape as the 98 virus continues to circulate in humans. 99 100

Related antibodies dominate the SARS-CoV-2 B-cell response in a convalescent donor 102

To study neutralizing antibody responses to SARS-CoV-2, we obtained a peripheral blood 103 sample from a healthy individual ("C1") who had been infected by SARS-CoV-2 five weeks prior 104 to sampling. Polyclonal immunoglobulin G (IgG) purified from the blood of this individual 105 neutralized SARS-CoV-2 but not vesicular stomatitis virus (VSV) lentivirus pseudotype (Fig. 1a) . 106 We generated a soluble SARS-CoV-2 S construct that is stabilized through mutations and the 107 addition of trimerization tag to adopt the S "pre-fusion" conformation ("S2P") 14 and used it as an 108 antigen to isolate 116 memory B cells (CD19 + , IgG + ) by FACS ( Supplementary Fig. 1a ). We could 109 produce 48 recombinant monoclonal antibodies in sufficient amount for further characterization. 110 Forty-three of these antibodies bound S2P by ELISA, and 18 also bound the RBD (Supplementary  111   Fig. 1b and Supplementary Table 1 ). Most antibodies were derived from the IGHV3 heavy chain 112 subgroup and had kappa light chains (Fig.1b) . Antibody CDR H3 and CDR L3 loops had an 113 average length of 15 and 9 amino acids, respectively, with low frequencies of somatic 114 hypermutation in variable heavy and light chain sequences (Fig.1c-d and Supplementary Table  115 1). 116

Of the 43 antibodies we tested, only eight neutralized SARS-CoV-2 pseudotype with 117 greater than 90% reduction in entry at a screening concentration of 100 µg ml -1 (Supplementary 118 Fig. 1c) . IC50 values ranged from 0.008 to 0.671 µg ml -1 in dose response pseudotype 119 neutralization assays ( Fig. 1e and Supplementary Fig. 2a) . These eight antibodies also 120 neutralized infectious SARS-CoV-2, but authentic virus was more resistant to antibody 121 neutralization than pseudotype ( Fig. 1e and Supplementary Fig. 2b) . 122

The only antibodies that neutralized infectious SARS- CoV-2 with an IC50 value of less than  123   1 µg ml -1 -C1A-B3, -F10, -C2, -H5, -C4, -B12, and -H6 -were somatic variants of the same  124   IGHV3-53/IGKV1-9-derived antibody (Supplementary Table 1) . Each had a low number of amino 125 acid substitutions in the heavy and light chain variable genes (Fig. 1e) . Monomeric Fabs derived 126 from these antibodies bound tightly to the RBD, with affinities ranging from 66 nM to 1 nM (Fig.  127 1e and Supplementary Fig. 3 ). C1A-B12, which we used as a representative member of the C1A-128 IGHV3 antibodies, prevented an ACE2-Fc fusion protein from binding to the RBD in a biolayer 129 interferometry (BLI)-based competition assay (Fig. 2a) . The Fab of CR3022, a human antibody 130 that does not compete with ACE2-binding 18 , did not affect C1A-B12 Fab or ACE2-Fc binding to 131 the RBD (Fig. 2a) . 132

To better understand the effects of somatic mutations on RBD affinity, we determined 134 X-ray crystal structures of the RBD bound to four Fabs: C1A-B3, -B12, -C2, and -F10 (Fig. 2b) . 135

The Fabs engage the RBD through an identical binding mode with root mean square deviations 136 (r.m.s.d.) of 0.36-0.39 Å by structural superposition. As with other IGHV3-53/IGHV3-66-derived 137 antibodies 4,8,10,12,19 , CDR loops H1, H2, H3, and L1 make the majority of RBD contacts (Fig. 2b) . 138

As suggested by the results of competition assays (Fig. 2a) , the antibodies and ACE2 bind the 139 same site on the RBD (Fig. 2c) . Most of the contacts are polar and involve backbone and 140 sidechain atoms on both sides of the interface (Fig. 2d-g) . Somatic mutations in the C1A-IGHV3-3 141 antibodies occurred in CDR loops and FWRs, and in the structure, some (e.g., the F10S and 142 S14F mutations in the light chain) are positioned far from the RBD and unlikely to impact antigen 143 affinity (Fig. 3) . As has been well described in antibody responses to influenza virus and HIV 20,21 , somatic 167 hypermutation that are not at antibody/antigen interfaces can nevertheless substantially 168 contribute to affinity gains by influencing CDR loop configuration and flexibility. The VH A24V 169 mutation is a pocket-filling mutation that, through hydrophobic interactions with the side chain of 170 VH F27, would rigidify CDR H1 may "pre-configure" it in a conformation that is compatible with 171 RBD binding ( Fig. 4i-j) . VH F27 is frequently mutated to a smaller hydrophobic residues during 172 somatic hypermutation; it is replaced by an isoleucine in C1A-H5, BD-604, and BD-236 8 , by a 173 leucine in CC12.1 12 , and by a valine in CV30 19 ( Fig. 4k; Supplementary Fig. 5a and 5c ). In contrast 174 to the VH A24V mutation, replacing VH F27 with smaller hydrophobic residue would likely make 175 CDR H1 more flexible as opposed to rigidifying it, and this added flexibility could allow optimization 176 of local polar contacts, particularly as additional mutations are introduced during affinity 177 maturation (the T28I change in addition to the F27V mutation in CV30) 19 ( Supplementary Fig.  178 5c). 179

Affinity is not the only property that may be beneficial to an effective antibody response 22 , 180 and antibody combining site diversity may provide broader protection against pathogens that are 181 antigenically variable and evolve over time 23 . As examples of BCR diversification that could result 182 in a loss of RBD affinity, the of VH S56A mutation in C1A-B12 removes a polar contact with RBD 183 D420, and the Y58F mutation in CC12.1 removes a polar contact with the backbone carbonyl of 184 RBD T415 ( Fig. 4f; Supplementary Fig. 5f-g) . 185

IGHV3-53/3-66-derived SARS-CoV-2 neutralizing antibodies usually have short CDR H3 186 loops to avoid clashes with the RBD surface 12 (Supplementary Fig. 4) . Six of the seven clonally 187 related IGH/V3-53 antibodies we isolated contain the S100aR mutation in CDR H3 with 188 independent substitutions at the nucleotide level ( Fig. 5a ), suggesting that this adaptation was 189 recurrently selected for during the affinity maturation process. We observed two alternate 190 conformations for the R100a side chain in the C1A-B12 Fab/RBD structure; it can either contact 191 the side chain of RBD Q493 or the backbone carbonyl of RBD S494 (Fig. 5b) . The R100a side 192 chain also helps position neighboring antibody residues to make additional contacts with the RBD 193 as part of a larger network of polar interactions involving water molecules. 194

To better understand the selective pressure driving the expansion of the IGVH3-53 class 196 of SARS-CoV-2 neutralizing antibodies and the role of the S100aR somatic change in affinity 197 maturation, we generated an antibody revertant in which all positions are reverted to their 198 germline counterparts (C1A-gl), and another that only retains the S100aR substitution (C1A-gl*) 199 ( Fig. 3 and Fig. 5c ). Monomeric C1A-gl and C1A-gl* Fabs bound the SARS-CoV-2 S RBD with 200 affinities of 127 nM and C1A-gl* and 46 nM, respectively ( Fig. 5d and Supplementary Fig. 3) . The 201 effect of the mutation was most pronounced on antibody on-rate, suggesting that the CDR H3 202 S100aR substitution allows the antibody to more effectively dock onto the RBD. C1A-gl and C1A-203 gl* IgG neutralized infectious SARS-CoV-2 with IC50 values of 0.126 and 0.102 µg ml -1 , 204 respectively ( Fig. 4e) . 205

We next sought to address whether C1A-IGHV3 antibodies could neutralize SARS-CoV-2 206 containing the D614G mutation in S, which is found in a circulating SARS-CoV-2 strain with 207 increased infectivity 24-26 . C1A-gl, which binds the RBD with 126 nM affinity, and C1A-B12, which 208 binds the RBD with thirty-fold higher affinity (KD of 4 nM), neutralized SARS-CoV-2 S D614G 209 pseudotypes with comparable IC50 values (74 and 34 ng ml -1 , respectively) ( Fig. 5f ). Taken 210 together, our results suggest that once a threshold RBD affinity is reached for IGHV3-53 211 antibodies, gains in affinity are not necessarily associated with more potent virus neutralization. Table 1 ), suggesting that in certain scenarios, the preponderance of such 225 antibodies could drive selective evolution of antibody neutralization escape. 226

The high "baseline affinity" IGHV3-53/3-66-derived germline antibodies have for the 227 SARS-CoV-2 RBD is likely driven by the extensive network of reciprocal polar contacts these 228 make with both main and side chain atoms of the RBD (Fig. 2, Fig. 3 , and Supplementary Fig. 5) . 229

Our ability to detect robust RBD binding for monomeric Fabs representing germline revertant 230 antibody sequences (Fig. 5 ) in an assay that does not take into account the avidity that would be 231 observed with B cell receptors engaging trimeric S suggests that strong selective pressure drives 232 the evolution of antibody responses against this epitope. Our results stand somewhat in contrast 233 to those observed with antibody CV30, an IGHV3-53/IGVΚ3-20 antibody for which reversion of 234 its only two substitutions (VH F27V and T28I) with respect to the germline antibody, results in a 235 change in affinity from 3.6 nM to 407 nM and in an almost sixty fold change in neutralization IC50 236 value (from 0.030 µg ml -1 to 16.5 µg ml -1 ) 19 . As described in our analysis, the VH F27V and T28I 237 mutations may respectively affect loop dynamicity and help optimize the geometry of CDR H1 238 contacts with the RBD 19 . The lack of a drastic change in affinity with reversion of germline antibody 239 sequences with C1A-IGHV3-53 antibodies suggest that these take better advantage of antigen 240 complementarity afforded by their CDR H3 loop and light chain gene (IGVK1-9 for C1A-IGHV3-241 53 antibodies and IGVK3-20 for CV30) (Supplementary Fig. 4) . 242

While we did not observe a correlation between RBD affinity and virus neutralization, we 243 did not measure affinities with full length SARS-CoV-2 S. IGHV3-53/3-66 neutralizing antibodies 244 can only bind the RBD when it is "up" 8,16 , and efficient virus neutralization by engagement of an 245 epitope that is transiently exposed likely requires optimization of binding on-and off-rates in 246 addition to gains in overall affinity. 247

Mutations that allow SARS-CoV-2 S to escape neutralization by antibodies that compete 248 with ACE2 binding have been observed in vitro 27 and recently in circulating strains 28 . Although 249 SARS-CoV-2 encodes an exonuclease that increases the fidelity of replication of its large RNA 250 genome, recurrence of an identical antibody response in multiple COVID-19 convalescent 251 individuals suggests that selective pressure against the RBD-binding site for ACE2 is substantial. 252

To broadly protect against emerging S variants and to counter evolution of neutralization escape and a C-terminal foldon trimerization motif followed by a BirA ligase site, a Tobacco Etch Virus 315 (TEV) protease site, a FLAG tag, and a His6-tag into a pHLsec vector 34 , which contains its own 316 secretion signal sequence. We note that two N-terminal S residues (residues 14 and 15) 317 downstream of the native S signal peptide were inadvertently omitted from the S2P construct 318 during subcloning. We transfected Expi293F TM cells using an ExpiFectamine TM transfection kit 319 (Thermo Fisher Scientific) according to the manufacturer's protocol. We purified the protein using 320 anti-FLAG M2 Affinity Gel (Sigma) according to manufacturer's protocol and removed the FLAG 321 tag and His6-tag with TEV digestion followed by reverse nickel affinity purification and size-322 exclusion chromatography on a Superose 6 Increase column (GE Healthcare Life Sciences). We 323 biotinylated the protein with BirA ligase as previously described 32 We subcloned constructs for the SARS-CoV-2 S RBD (GenBank ID: QHD43416.1 residues 319-339 541) into the pHLsec 34 vector for use in ELISAs, BLI binding studies, and X-ray crystallography. 340

For ELISAs and crystallography the construct includes an N-terminal His6-tag, a TEV protease 341 site and a short linker (amino acids SGSG). For BLI-binding assays, the construct includes an N-342 terminal His6-tag, followed by a TEV protease site, a BirA ligase site, and a 7-residue linker. We 343 produced protein for ELISA and BLI-binding assays by using linear polyethylenimine (PEI) to 344 transfect HEK293T cells grown in suspension and purified by nickel affinity purification. For BLI-345 binding assays the protein was digested with TEV protease to remove the His6-tag followed by 346 reverse nickel affinity purification. We biotinylated protein with BirA ligase as previously 347 described 35 , followed by a reverse nickel affinity purification step to remove BirA ligase, which 348 contains a His6-tag and cannot be separated by size exclusion chromatography from the SARS-349

CoV-2 RBD due to its similar size. For crystallography, we produced the protein by PEI 350

and also in presence of kifunensine (5 µM), purified by nickel affinity purification, and removed 352 the His6-tag by TEV digestion followed by reverse nickel affinity purification. As a final step, we 353 used size exclusion on a S200 Increase column, in which each recombinant RBD protein ran as 354 a single peak at the expected retention volume. subsequently measured in PRNT assay 46 . Monoclonal antibody mAb114 is included as a control. Each 718 monoclonal antibody was serially diluted in Dulbecco's phosphate Buffered Saline (DPBS) using half-719 log dilutions starting at a concentration of 50 µg ml -1 . Means ± standard deviation from three 720 experiments performed in triplicate (n=9). Data are normalized to a no antibody control. For some data 721 points, error bars are smaller than symbols. 722 723

Somatic mutations of the immunoglobulin framework are generally 560 required for broad and potent HIV-1 neutralization

Affinity enhancement of antibodies: how low-affinity antibodies produced 563 early in immune responses are followed by high-affinity antibodies later and in memory 564 B-cell responses

Affinity 567 maturation in a human humoral response to influenza hemagglutinin

Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G

Increases Infectivity of the COVID-19 Virus

The D614G mutation in the SARS-CoV-2 spike protein reduces S1 573 shedding and increases infectivity. bioRxiv

Structural and Functional Analysis of the D614G SARS-CoV-2

Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational 577 escape seen with individual antibodies

The circulating SARS-CoV-2 spike variant N439K maintains 580 fitness while evading antibody-mediated immunity. bioRxiv

A method for identification of HIV gp140 binding memory B cells in 583 human blood

Sequence and structural convergence of broad and potent HIV 585 antibodies that mimic CD4 binding

IMGT/V-QUEST: the highly customized and 588 integrated system for IG and TR standardized V-J and V-D-J sequence analysis

Vaccine-elicited receptor-binding site antibodies neutralize two New 591 World hemorrhagic fever arenaviruses

Severe Acute Respiratory Syndrome Coronavirus 2 from Patient with 594 Coronavirus Disease, United States

A time-and cost-efficient system for high-level 597 protein production in mammalian cells

Molecular Basis for Antibody-Mediated Neutralization of New 600 World Hemorrhagic Fever Mammarenaviruses

How good are my data and what is the resolution

Phaser crystallographic software

Improved methods for building 610 protein models in electron density maps and the location of errors in these models

PHENIX: a comprehensive Python-based system for macromolecular 613 structure solution

BUSTER version 2.10.3., (Global Phasing Ltd

Transferrin receptor 1 is a cellular receptor for New World 617 haemorrhagic fever arenaviruses

Genome-wide CRISPR screen in a mouse model of tumor growth and 619 metastasis

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the 621 ACE2 receptor

Deciphering key features in protein structures with the new 623 ENDscript server

Cellular Nanosponges Inhibit SARS-CoV-2 Infectivity

Antibody somatic mutations at the SARS-CoV-2 RBD interface. Interactions of CDR H1 671 residue 31 with the RBD are shown for C1A-B3 (a), C1A-C2 (b)

Interactions occurring at the base of CDR H1 near the framework regions are shown for C1A-B3 675 (I), C1A-C2 (j), or BD-236 (PDB: 7CHB) 8 (k). The color scheme for the RBD and antibody Fab is the 676 same as the one showed in Figure 2b

Supplementary Figure 1. Monoclonal antibody isolation from a COVID-19 convalescent 696 individual. (a) Density plot from a FACS experiment to isolate memory B cells that bind phycoerythrin 697 (PE)-labelled streptavidin tetramers coupled to a prefusion-stabilized SARS-CoV-2 S construct

The left panel is for a control donor and the right panel is for a COVID-700 19 convalescent donor. CD19 is a B-cell marker. (b) Whisker plot showing ELISA values for IgG 701 binding to S2P, the SARS-CoV-2 RBD, or the control protein Lujo virus (LUJV) GP1. Antibodies were 702 added at a single concentration of 100 µg ml -1 . (c) SARS-CoV-2 lentivirus pseudotypes were pre-703 incubated with 100 µg ml -1 of the indicated IgG or ACE2-Fc fusion protein (ACE2-Fc) and the mixture 704 was used to infect HEK293T-hACE2 cells. Entry levels were quantified 48 h later using FACS. VSV 705 lentivirus pseudotype is included as a control

Red lines 726 represent the fit for a 1:1 binding model, and alternate colors represent response curves measured at 727 varying concentrations. Binding kinetics were measured for six concentrations of Fab at 2-fold dilution 728 ranging from 500 to 15.6 nM (for Fab C1A-B3

Gene 734 usage and CDR H3 lengths IGVH3-53/3-66 antibodies included in our analysis. CDR H3 length was 735 determined using IMGT/V-QUEST definitions 31 . (b) Structural alignment of variable heavy (VH) and 736 variable light (VL) portion of Fabs derived from IGHV3-53/3-66 bound to the SARS-CoV-2 RBD for all 737 antibodies listed in (a)

antibodies. (a) Alignment of variable heavy chain and (b) IGLVK1-9-derived light chain sequences of 741 IGHV3-53/3-66 antibody genes reported here and elsewhere. Antibody sequences were obtained from 742 the RCSB record and protein data bank (PDB) IDs listed in Fig S4A

ESPrit3 45 and modified. The Kabat numbering scheme is used. (c) CV30-Fab/RBD complex (PDB: 744 6XE1 19 showing interactions occurring with CDR H1 mutations F27V and T28I. (d) B38 Fab/RBD 745 complex (PDB: 7BZ5) 4 showing interactions occurring with the CDR H1 T28I mutation

PDB: 7CH5) 8 showing interactions occurring with the CDR H1 G26E and T28I 747 mutations. (f) C1A-B3 Fab/RBD complex showing interactions occurring with the germline CDR H2 748 residue Y52. (g) CC12.1 Fab/RBD complex (PDB: 6XC2) 12 showing interactions with the Y58F

Supplementary Table 1. Properties of monoclonal antibodies isolated from a COVID-19 convalescent

Antibodies highlighted in gray are somatic variants of the same antibody. CDR loop lengths are shown 781 as numbers of amino acids

Supplementary Table 2. Data collection and refinement statistics 786 787 C1A-B3/RBD a (PDB 7KFV)

C1A-F10/RBD a (PDB 7KFY) Data collection Space group P212121 P212121 C2221 C2221 Cell dimensions a, b